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CLARIFICATION OF MEDICAL POLICY
FOR SKIN LESION REMOVAL

The purpose of this communication is to clarify the reference to
Efudex topical cream contained in our local medical review policy
(LMRP) for skin lesion removal. This policy was published in the
October, 1996 special edition of the "Medicare B Update!"
The above referenced policy in no way circumvents physician
judgment. The skin lesion LMRP simply seeks to articulate when
excision or destruction (e.g., laser treatment, chemical treatments) .is
considered medically necessary. There are clinical criteria cited in the
skin lesion LMRP that constitute appropriateness. Several of the
criteria are:

.

•

When the patient presents with an actinic keratosis that has
changed in size, has developed erythema, has thickened, has
ulcerated, has ernded, has developed changes at the tumor
margins, has become ·m arkedly hyperkeratotic, in which pain has
developed and/or a cutaneous horn has develo_ped;

•

When the patient presents with an actinic keratosis of the
lower-lip, upper-lip, conjunctivae, nose, ear, or eyelid;

•

When the patient presents with actinic keratosis and has a
history· of one of the following: chronic immunosuppression,
treatment of psoriasis with psoralen-ultrayiolet A (PUVA)'
therapy, xeroderma pigmentosum, albinism, or · discoid lupus
erythematosus, and/or previous treatment of a biopsy-proven
Squamous Cell Carcinoma or other skin malignancy;

•

When a patient presents with a keratosis and has a history of
significant exposure to therapeutic or occupational radiation
therapy;

•

When the patient has multiple actinic keratoses and has selfadministered 2 % to 5 % Efudex topical cream for two to four
weeks and the actinic keratoses have not responded to this
treatment one to two months following treatment .
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There has been considerable misunderstanding of the reference to
Efudex. A fundamental principal in the policy is that treatment of
asymptomatic actinic keratosis is medically unnecessary. This would
be true for any method of treatment, e.g., surgical, laser or cryogenic
destruction, or use of topical creams_(chemical destruction). Because
literature indicates that lesions failing topical treatment with Efudex
suggests a higher likelihood of malignancy, we have allowed for
coverage in these cases.
In other words, a failure of Efudex
establishes a clinical criterion for a lesion being suspicious versus
asymptomatic.
In short, our skin lesion LMRP lays out the criteria for when the
removal of skin lesions is approp.r iate.
The policy both reduces
inappropriate billing and protects beneficiaries from unnecessary
procedures. Should additional medical literature or other information
relevant to this matter become available, providers are always free to
contact us and request policy changes. In addition, we continue to
offer formal appeal rights to providers who believe their claims were
improperly denied.
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